Equities
Health CareHealth Care Providers
  • Price (GBX)11.00
  • Today's Change0.00 / 0.00%
  • Shares traded124.08k
  • 1 Year change-90.43%
  • Beta1.8422
Data delayed at least 20 minutes, as of Jul 04 2024 13:47 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

  • Revenue in GBP (TTM)2.67m
  • Net income in GBP-36.28m
  • Incorporated2018
  • Employees80.00
  • Location
    Renalytix PLCFinsgate, 5-7 Cranwood StreetLONDON EC1V 9EEUnited KingdomGBR
  • Phone+44 292 071 0570
  • Websitehttps://renalytix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genedrive PLC272.00k-5.00m9.10m43.00--1.70--33.45-0.0407-0.04070.00220.00980.0658--1.606,325.58-120.84-97.55-197.86-128.51-----1,837.50-797.031.36-7.490.0789--12.24-50.95-10.16--16.72--
Feedback plc886.00k-3.49m9.13m24.00--1.02--10.31-0.2614-0.26140.06640.67260.0774--3.7436,916.67-30.44-28.58-32.67-31.7490.6092.61-393.47-299.13----0.00--74.1517.46-37.74--56.22--
Proteome Sciences plc5.03m-2.44m11.07m35.00------2.20-0.0083-0.00830.017-0.01040.42093.893.04143,657.10-20.45-1.22----32.7654.53-48.59-2.200.2667-2.031.29---35.3710.52-284.38--126.22--
Inspiration Healthcare Group PLC37.63m-6.32m11.94m210.00--0.4122--0.3173-0.0925-0.09250.55160.42450.72431.673.66---12.170.8965-14.861.1047.5347.61-16.800.99220.9698-0.91720.307---8.7419.43-2,423.90--31.88--
Genincode PLC2.16m-7.02m11.95m36.00--5.02--5.53-0.0732-0.07320.02250.01350.270321.883.3360,000.00-87.79---124.10--47.31---324.81--1.24--0.1883--51.05---26.21------
Abingdon Health PLC5.34m-2.24m12.99m82.00--6.88--2.43-0.0184-0.01840.04390.01490.89787.674.7465,170.73-37.55-51.31-58.04-79.8557.3533.16-41.82-139.641.59--0.3572--42.68--83.77------
Verici DX PLC795.13k-6.86m15.77m14.00--3.96--19.83-0.0403-0.04030.00470.01640.0932--1.5956,795.29-80.32---115.94--1.58---862.19------0.0438------23.43------
Renalytix PLC2.67m-36.28m16.98m80.00--0.7122--6.36-0.4441-0.44410.03250.15450.06462.884.0633,388.96-87.73-58.25-120.00-67.0320.60---1,358.30-1,904.791.71-9.620.397--14.58--18.52------
Polarean Imaging PLC699.32k-9.33m20.82m29.00--0.6701--29.77-0.0372-0.03720.00280.02570.05330.28240.759924,114.40-71.12-61.45-81.95-69.1737.6650.68-1,333.98-810.923.11--0.0255---13.75-18.2414.53--64.51--
Ondine Biomedical Inc692.38k-8.29m21.45m43.00--14.62--30.99-0.0421-0.04210.00350.00530.10790.42374.74---129.24---193.37--58.44---1,198.01--1.06--0.206--88.56--25.60------
Belluscura PLC647.89k-14.54m24.94m24.00--1.48--38.50-0.1101-0.11010.0050.1010.03720.21180.1975---83.37-49.84-96.68-54.78-50.80-37.48-2,243.45-1,277.341.71-4.07-----40.9627.44-127.13--41.32--
Data as of Jul 04 2024. Currency figures normalised to Renalytix PLC's reporting currency: UK Pound GBX

Institutional shareholders

33.22%Per cent of shares held by top holders
HolderShares% Held
Polar Capital LLPas of 30 Apr 202413.87m8.98%
Harwood Capital LLPas of 15 Mar 202410.78m6.98%
Jefferson River Capital LLCas of 10 Apr 20248.53m5.53%
Pentwater Capital Management LPas of 24 Apr 20245.79m3.75%
Lombard Odier Asset Management (Europe) Ltd.as of 24 Apr 20244.00m2.59%
Susquehanna Investment Group LLCas of 18 Jun 20242.30m1.49%
Heights Capital Management, Inc.as of 24 Jun 20242.27m1.47%
Gilder, Gagnon, Howe & Co. LLCas of 12 Mar 20241.52m0.99%
Unicorn Asset Management Ltd.as of 04 Mar 20241.18m0.76%
Chelverton Asset Management Ltd.as of 30 Jun 20231.05m0.68%
More ▼
Data from 31 Mar 2023 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.